- Dosing of first subject in clinical trial by Pfizer triggers US$5 million payment to Sosei Heptares
- Third candidate nominated by Pfizer to enter clinical trials is an MC4 receptor antagonist targeting Anorexia
- Ninth GPCR-targeted drug candidate overall generated from Sosei Heptares' StaR® technology/SBDD platform to enter clinical development
PR Newswire
TOKYO and CAMBRIDGE, England, May 19, 2021